Debbie Rigby takes a look at the latest in research news related to pharmacy
Rhinosinusitis is characterised by symptomatic inflammation of the nasal cavity and paranasal sinuses that decreases quality of life. The treatment of acute rhinosinusitis primarily involves symptomatic control with intranasal corticosteroids and nasal saline irrigation. Antibiotics should be reserved for the patients who are believed to have bacterial rhinosinusitis. Treating chronic rhinosinusitis involves using intranasal corticosteroids and irrigation, systemic corticosteroids, and potentially systemic antibiotics.
Curr Opin Allergy Clin Immunol. 2016;16(4):383-389.
A large nested case-control study has confirmed that current use of any NSAID (use in preceding 14 days) is associated with a 19% increase of risk of hospital admission for heart failure. The risk of admission for heart failure increased for traditional NSAIDs (diclofenac, ibuprofen, indomethacin, ketorolac, naproxen, and piroxicam) and two COX 2 inhibitors (etoricoxib and rofecoxib). Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses. However, there was no evidence that celecoxib increased the risk of admission for heart failure at commonly used doses.
A large 26 week study of 11,693 patients aged 12 years and older with moderate-to-severe asthma has demonstrated that treatment with budesonide–eformoterol is associated with a lower risk of asthma exacerbations than budesonide and a similar risk of serious asthma-related events.
N Engl J Med 2016; 375:850-860.
A RCT of children with asthma, aged 4 to 11 years, has shown that salmeterol in a fixed-dose combination with fluticasone is associated with the risk of a serious asthma-related event that was similar to the risk with fluticasone alone. Children included in the trial, which was conducted over 6 months, used daily asthma medications and had a history of asthma exacerbations in the previous year.
N Engl J Med 2016; 375:840-849.